NCT06281158View on ClinicalTrials.gov

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

[14C]-DNL343

Single dose

Trial Locations (1)

53704

Clinical Site, Madison

Sponsors
All Listed Sponsors
lead

Denali Therapeutics Inc.

INDUSTRY

NCT06281158 - A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants | Biotech Hunter | Biotech Hunter